📢 Announcing: The new SK pharmteco website! www.skpharmteco.com We are live! Designed with you in mind, our new site reflects our commitment to innovation, transparency, and providing best-in-class CDMO and Contract Analytical Testing solutions for our partners. Explore our new website to learn more about: 🔸𝗛𝗼𝘄 𝘄𝗲 𝘄𝗼𝗿𝗸 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀: See how simplicity and transparency make us an easy-to-work-with CDMO. 🔸𝗢𝘂𝗿 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀: Dive into our advanced offerings in small molecules, cell and gene therapies, and analytical services. 🔸𝗢𝘂𝗿 𝗴𝗹𝗼𝗯𝗮𝗹 𝗻𝗲𝘁𝘄𝗼𝗿𝗸: Learn about our high-capacity facilities delivering excellence across the globe 🔸𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Stay up-to-date with industry insights and SK pharmteco news Check it out today and discover how we’re inspiring waves of change and impacting the landscape of pharmaceutical manufacturing: www.skpharmteco.com #CDMO #innovation #SKpharmteco #websitelaunch #globalsolutions
소개
Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group.
- 웹사이트
-
https://www.skpharmteco.com
SK pharmteco 외부 링크
- 업계
- 제약
- 회사 규모
- 직원 1,001 - 5,000명
- 본사
- California Rancho Cordova
- 유형
- 비상장기업
- 전문 분야
- HPAPI, High Potency API, Energetic Chemistry, Continuous Flow Process, Controlled Substances, Particle Engineering, Simulated Moving Bed Technology, Fine Chemicals, Intermediates, Analytical Services, API, Drug Development, Research & Development, Contract Manufacturing, Tech Transfer, Registered Starting Materials, Biologics, Antibody Conjugates (linkers & payloads) , Chromatography, Analytical Services, Cell and Gene Therapy, CDMO 및 viral vector
위치
SK pharmteco 직원
업데이트
-
We're attending Advanced Therapies Week 2025! Don't miss John Bowen, Senior Director of Nucleic Acids and Plasmid Operations at SK pharmteco, as he presents: 𝗣𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻: 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗖𝗚𝗠𝗣 𝗣𝗹𝗮𝘀𝗺𝗶𝗱𝘀 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 Key Takeaways: 🔸Overview of SK pharmteco’s unique features and advantages of a plasmids platform 🔸Scalability and customization to meet diverse industry needs. 🔸Vision for the future, our roadmap for continuous innovation, and reducing CoGs in plasmids manufacturing 📅 When: Thursday, January 23, 11:45 AM 📍 Where: Theater # 2 See you there! Want to schedule a meeting? Click here 👉 https://lnkd.in/eDDuKz75 Phacilitate #ATW25 #advancedtherapies #plasmids #CDMO
-
-
That’s a wrap on 2024! From strengthening global partnerships to connecting with you at countless events and celebrating key milestones, we’re taking a moment to reflect on an incredible year at SK pharmteco. Swipe through to see our 2024 Wrapped 👉
-
All of us at SK pharmteco are wishing you and yours a joyful holiday season filled with peace and happiness. Thank you for being a part of our journey this year – we look forward to achieving even greater things together in the year ahead!
-
-
SK pharmteco will be in San Francisco during the J.P. Morgan Healthcare Conference and would love to connect! Set up a meeting with Joerg Ahlgrimm, John Lee, or Steve Barr to discuss partnerships, innovations in advanced therapies, or explore how we can collaborate: https://lnkd.in/eGXdKy4U #CDMO #JMP25 #advancedtherapies
-
-
Want to stay in the know? Check out our new and improved News & Insights page where you’ll find comprehensive resources right at your fingertips. Dive in to explore the latest industry trends, expert insight, events, and CDMO news: https://lnkd.in/eQpEWCGk #CDMO #pharma #smallmolecules #cellandgenetherapy #analyticalservices
-
-
As we close out 2024, Joerg Ahlgrimm, CEO of SK pharmteco, reflects on some milestones that defined the year: 🔸Expanded our capabilities in Korea and Ireland 🔸Strengthened our unified global brand 🔸Launched our new website, making it easier than ever to explore how we deliver excellence across modalities. Looking ahead to 2025, we’re energized to keep innovating, collaborating, and driving even greater success for our partners and the patients we ultimately serve. Ready to see how we can support your next 2025 project? Take a look at our new website to experience the possibilities: www.skpharmteco.com #CDMO #Innovation #GlobalSolutions
-
The SK pharmteco team recently had the pleasure of attending the Biomanufacturing World Summit, where John Lee, Global Head of Cell & Gene Therapy, participated in a compelling panel discussion on Agile Manufacturing: Technical Strategies for Operational Flexibility. Missed the panel at #BMWS24? Catch it on-demand and discover insights into operational adaptability: https://lnkd.in/exfyeXcP #Biomanufacturing #CellandGeneTherapy
-
-
Regulatory agencies worldwide are continuously refining acceptable intake limits for nitrosamines, harmonizing on risk-based assessments to ensure patient safety. Staying ahead in this evolving landscape requires robust method development and validation processes. In a recent webinar, SK pharmteco’s Shankar Sankaran dives into: 🔸 The regulatory landscape for nitrosamines and nitrosamine drug substance-related impurities (NDSRIs) 🔸 Selecting the right analytical technologies for nitrosamines assessment 🔸 Understand different method development and validation strategies. Check out the full webinar here to learn more: https://lnkd.in/eh5mWn8M #nitrosamines #analyticalservices #APIs #pharmaceuticalmanufacturing